[
  {
    "ts": "2025-09-30T20:05:40+00:00",
    "headline": "Masimo, Integra LifeSciences, CONMED, IQVIA, and Charles River Laboratories Shares Are Soaring, What You Need To Know",
    "summary": "A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry. The Trump administration is advancing its “Most Favored Nation” initiative, which aims to lower prescription drug costs for Americans. This policy would tie the prices of medications in the U.S. to the lowest costs paid by other wealthy nations. As part of this push, Pfizer has reportedly entered into an agreement to voluntarily sel",
    "url": "https://finance.yahoo.com/news/masimo-integra-lifesciences-conmed-iqvia-200540531.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "a74a1415-2a4a-3fd8-9012-8645b4398b45",
      "content": {
        "id": "a74a1415-2a4a-3fd8-9012-8645b4398b45",
        "contentType": "STORY",
        "title": "Masimo, Integra LifeSciences, CONMED, IQVIA, and Charles River Laboratories Shares Are Soaring, What You Need To Know",
        "description": "",
        "summary": "A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry. The Trump administration is advancing its “Most Favored Nation” initiative, which aims to lower prescription drug costs for Americans. This policy would tie the prices of medications in the U.S. to the lowest costs paid by other wealthy nations. As part of this push, Pfizer has reportedly entered into an agreement to voluntarily sel",
        "pubDate": "2025-09-30T20:05:40Z",
        "displayTime": "2025-09-30T20:05:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/d5c4fd0f3134073f515b00835af29c87",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "MASI Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0XAhorRP0BUACQIaeuZ10Q--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/d5c4fd0f3134073f515b00835af29c87.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eRTjdOoOTTe6MSWKHoI0Kw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/d5c4fd0f3134073f515b00835af29c87.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/masimo-integra-lifesciences-conmed-iqvia-200540531.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/masimo-integra-lifesciences-conmed-iqvia-200540531.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IQV"
            },
            {
              "symbol": "CNMD"
            },
            {
              "symbol": "MASI"
            },
            {
              "symbol": "IART"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "CRL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]